Changes this week
Changes detected in the 7 days to Nov 20, 2026
- Notable: REC-1245 · Unresectable, Locally Advanced, or Metastatic Cancer Primary and study completion pushed from Oct 30, 2028 to Jul 2029
- Notable: SNH-119014 · Non-transfusion-dependent Thalassemia (NTDT) Primary completion pushed from Mar 29, 2027 to Sep 30, 2027
- Notable: Abemaciclib and Elacestrant · Brain Metastasis Due to ER+/HER-2- Breast Cancer Primary completion pushed from Dec 2026 to Aug 2027
- Notable: Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6 Years Old Primary completion pushed from Jun 2026 to Jun 2027
- Notable: (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study Primary completion pushed from Aug 2026 to Aug 2027
- Notable: Efficiency of Cytoflavin, · Ischemic Stroke Not Receiving Reperfusion Therapy Primary completion pushed from Sep 30, 2025 to Jun 1, 2027
- Notable: Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time · Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Primary and study completion pushed from Mar 31, 2031 to Jun 30, 2034
- Notable: STIMIT Activator 1 IDE Study Primary completion pushed from Apr 2026 to Jan 2027
- Notable: MyoTrain System in a Population · Trans-radial Limb Loss Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2027
- Notable: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) Primary completion pushed from Jul 1, 2027 to Feb 1, 2028
- Notable: SA of the Supira System for HRPCI Primary completion pushed from Apr 30, 2025 to Feb 6, 2026
- Notable: KPAP Adherence Crossover Study Primary completion pushed from Dec 1, 2026 to Dec 1, 2027
- Notable: MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
- Notable: MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
- Notable: Antibiotic Prophylaxis in Rhinoplasty Primary completion pushed from Dec 20, 2026 to Dec 20, 2027
- Notable: LOG-I - Impact Study of LOG-AFTER Software on Long-term Monitoring of Former Patients (LOG-I - LOG-Impact Study) Primary completion pushed from Nov 6, 2026 to Dec 5, 2027
- Notable: Alleviating Carbohydrate Counting · Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide Primary and study completion pushed from Jan 2027 to Dec 2027
- Notable: Project: Every Child for Younger · Cancer Primary and study completion pushed from Dec 31, 2030 to Dec 31, 2032
- Notable: Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia Primary and study completion pushed from Dec 2026 to Dec 2027
- Notable: Treatment of Language Impairment in Young · Autism Spectrum Disorder With Leucovorin Calcium Primary and study completion pushed from Jul 31, 2026 to Jan 31, 2027
- Notable: Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy · B Acute Lymphoblastic Leukemia Primary and study completion pushed from Nov 1, 2026 to Nov 1, 2028
- Notable: Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin Primary completion pushed from Dec 30, 2026 to Dec 31, 2027
- Notable: Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation Primary completion pushed from Oct 18, 2027 to Oct 18, 2029
- Notable: Post-Transplant Cyclophosphamide, Bortezomib and Abatacept · Graft-versus-Host-Disease (GvHD) Primary completion pushed from Aug 2026 to Nov 2027
- Notable: Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib Primary completion pushed from Oct 15, 2028 to May 15, 2029
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates